DC
MRNS

Diametric Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Diametric Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,986
Closed -$131K – 493
2023
Q1 		$131K Buy
+18,986
New +$119K 0.06% 251

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Diametric Capital's MRNS Position: Q2 2023 in Review

Diametric Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 18,986 shares — an estimated $131K sold.

Diametric Capital first reported a position in MRNS in Q1 2023 and held it in 1 quarter. The position peaked at $131K in Q1 2023. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • Diametric Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 18,986 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $131K.
  • Diametric Capital first reported a position in Marinus Pharmaceuticals, Inc in Q1 2023 and held it in 1 quarter.
  • Diametric Capital's Marinus Pharmaceuticals, Inc position peaked at $131K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.